Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials

Published:2024-08 Issue:8 Volume:6 Page:100855
ISSN:2590-0595
Container-title:Kidney Medicine
language:en
Short-container-title:Kidney Medicine

Author:

Dixon Bradley P.^ORCID,Kavanagh David,Aris Alvaro Domingo Madrid,Adams Brigitte,Kang Hee Gyung,Wang Edward,Garlo Katherine,Ogawa Masayo,Amancha Praveen,Chakravarty Sourish,Heyne Nils,Kim Seong Heon,Cataland Spero,Yoon Sung-Soo,Miyakawa Yoshitaka,Luque Yosu,Muff-Luett Melissa,Tanaka Kazuki,Greenbaum Larry A.

Funder

Alexion Pharmaceuticals Inc

Publisher

Elsevier BV

Reference22 articles.

1. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference;Goodship;Kidney Int,2017

2. Haemolytic uraemic syndrome;Fakhouri;Lancet,2017

3. Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment;Raina;Ther Apher Dial,2019

4. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults;Fremeaux-Bacchi;Clin J Am Soc Nephrol,2013

5. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype;Noris;Clin J Am Soc Nephrol,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP